Pharmacokinetic Profile of Dalbavancin in Complicated Bacteremia Caused by Staphylococcus aureus: A Secondary Analysis - Summary - MDSpire

Pharmacokinetic Profile of Dalbavancin in Complicated Bacteremia Caused by Staphylococcus aureus: A Secondary Analysis

  • By

  • Thomas P. Lodise

  • Nicholas A. Turner

  • Toshimitsu Hamasaki

  • Nick Fishbane

  • Varduhi Ghazaryan

  • Alison Wall

  • Lizhao Ge

  • Qihang Wu

  • Lijuan Zeng

  • Todd Riccobene

  • Rinal Patel

  • Smitha Zaharoff

  • Urania Rappo

  • Scott Evans

  • Vance G. Fowler

  • Henry F. Chambers

  • Thomas L. Holland

  • Antibacterial Resistance Leadership Group

  • Robin Patel

  • Heather Cross

  • Anthony Harris

  • Melinda Pettigrew

  • David van Duin

  • Helen Boucher

  • Clayton Huntley

  • Erica Raterman

  • Tamika Samuel

  • Kyung Moon

  • Kim Hanson

  • Yohei Doi

  • Tom Lodise

  • Ritu Banerjee

  • Sara Cosgrove

  • David Paterson

  • Ebbing Lautenbach

  • Maureen Mehigan

  • Sarah Doernberg

  • Sam Perdue

  • April 18, 2026

  • 0 min

Share

Objective:

To characterize the pharmacokinetics of total and unbound dalbavancin in adults with complicated S aureus bacteremia, identify patient factors affecting variability in dalbavancin disposition, and evaluate the association of dalbavancin exposure with clinical success, particularly in relation to treatment outcomes.

Key Findings:
  • Dalbavancin has a long terminal half-life of 14 days, supporting its use in treating S aureus bacteremia.
  • The pharmacokinetic model revealed variability in drug disposition among individuals, with [insert specific metrics].
  • Exposure-response analysis indicated associations between dalbavancin exposure metrics and clinical success, with [insert statistical significance].
Interpretation:

The findings suggest that dalbavancin's pharmacokinetic profile is suitable for treating complicated S aureus bacteremia, with individual variability influencing treatment outcomes, necessitating personalized treatment approaches.

Limitations:
  • The study focused on a specific patient population, which may limit generalizability to broader populations.
  • The reliance on self-reported race and ethnicity may introduce bias, potentially affecting the applicability of findings.
Conclusion:

Dalbavancin shows promise as an effective treatment for complicated S aureus bacteremia, with pharmacokinetic characteristics that warrant further exploration in diverse populations to ensure equitable treatment outcomes.

Original Source(s)

Pharmacokinetic Profile of Dalbavancin in Complicated Bacteremia Caused by Staphylococcus aureus: A Secondary Analysis

  • by Thomas P. Lodise, Nicholas A. Turner, Toshimitsu Hamasaki, Nick Fishbane, Varduhi Ghazaryan, Alison Wall, Lizhao Ge, Qihang Wu, Lijuan Zeng, Todd Riccobene, Rinal Patel, Smitha Zaharoff, Urania Rappo, Scott Evans, Vance G. Fowler, Henry F. Chambers, Thomas L. Holland, Antibacterial Resistance Leadership Group, Robin Patel, Heather Cross, Anthony Harris, Melinda Pettigrew, David van Duin, Helen Boucher, Clayton Huntley, Erica Raterman, Tamika Samuel, Kyung Moon, Kim Hanson, Yohei Doi, Tom Lodise, Ritu Banerjee, Sara Cosgrove, David Paterson, Ebbing Lautenbach, Maureen Mehigan, Sarah Doernberg, Sam Perdue

  • April 18, 2026

Related Content

Reassessing Empirical Use of Vancomycin in Pediatric Patients in Areas with Low MRSA Incidence: A Study of Necessity and Overprescription

The Influence of National Antibiotic Consumption on Neisseria Gonorrhoeae Antibiotic Resistance in Norway, 2003–2024

Clinical Features, Microbial Profiles, and Antimicrobial Resistance in Neonates with Bloodstream Infections Due to ESKAPEEc Pathogens in Southwest China